iPath® B S&P 500® VIX Md-Trm Futs™ ETN SEC Filings

Barclays Bank PLC is marketing Partial Principal at Risk Securities linked to the S&P 500® Index. The $1,000-denominated notes will be priced on 30 June 2025 and mature on 5 January 2027. They offer a 100% participation rate in any positive index return, but total upside is capped at a maximum payment of at least $1,127 (≥ 112.7% of principal). If the index ends below its initial level, holders receive principal reduced by the index’s percentage decline, subject to a minimum payment of $850; the worst-case loss is therefore 15% of invested capital.

The notes pay no periodic interest, are senior unsecured obligations of Barclays, and are exposed to both the bank’s credit risk and potential U.K. bail-in. Barclays’ own pricing models value the securities at $919.90–$969.90, noticeably below the $1,000 issue price, reflecting dealer compensation, hedging costs and structuring margin.

No exchange listing is planned, so liquidity will depend on Barclays making markets, and resale prices may be well below both issue price and model value. Additional risks disclosed include limited upside, potential negative impact of Barclays’ hedging, model uncertainty, and possible early acceleration upon regulatory change-in-law events.

These notes may suit investors seeking moderate, capped equity exposure with partial downside protection over an 18-month horizon, but investors give up dividends, accept limited upside and bear issuer and market liquidity risk.

Barclays Bank PLC is marketing Partial Principal at Risk Securities linked to the S&P 500® Index. The $1,000-denominated notes will be priced on 30 June 2025 and mature on 5 January 2027. They offer a 100% participation rate in any positive index return, but total upside is capped at a maximum payment of at least $1,127 (≥ 112.7% of principal). If the index ends below its initial level, holders receive principal reduced by the index’s percentage decline, subject to a minimum payment of $850; the worst-case loss is therefore 15% of invested capital.

The notes pay no periodic interest, are senior unsecured obligations of Barclays, and are exposed to both the bank’s credit risk and potential U.K. bail-in. Barclays’ own pricing models value the securities at $919.90–$969.90, noticeably below the $1,000 issue price, reflecting dealer compensation, hedging costs and structuring margin.

No exchange listing is planned, so liquidity will depend on Barclays making markets, and resale prices may be well below both issue price and model value. Additional risks disclosed include limited upside, potential negative impact of Barclays’ hedging, model uncertainty, and possible early acceleration upon regulatory change-in-law events.

These notes may suit investors seeking moderate, capped equity exposure with partial downside protection over an 18-month horizon, but investors give up dividends, accept limited upside and bear issuer and market liquidity risk.

Barclays Bank PLC is marketing Partial Principal at Risk Securities linked to the S&P 500® Index. The $1,000-denominated notes will be priced on 30 June 2025 and mature on 5 January 2027. They offer a 100% participation rate in any positive index return, but total upside is capped at a maximum payment of at least $1,127 (≥ 112.7% of principal). If the index ends below its initial level, holders receive principal reduced by the index’s percentage decline, subject to a minimum payment of $850; the worst-case loss is therefore 15% of invested capital.

The notes pay no periodic interest, are senior unsecured obligations of Barclays, and are exposed to both the bank’s credit risk and potential U.K. bail-in. Barclays’ own pricing models value the securities at $919.90–$969.90, noticeably below the $1,000 issue price, reflecting dealer compensation, hedging costs and structuring margin.

No exchange listing is planned, so liquidity will depend on Barclays making markets, and resale prices may be well below both issue price and model value. Additional risks disclosed include limited upside, potential negative impact of Barclays’ hedging, model uncertainty, and possible early acceleration upon regulatory change-in-law events.

These notes may suit investors seeking moderate, capped equity exposure with partial downside protection over an 18-month horizon, but investors give up dividends, accept limited upside and bear issuer and market liquidity risk.

Kineta, LLC (successor by merger to Kineta, Inc.) has filed Post-Effective Amendment No. 1 to nine Form S-8 registration statements to deregister all unsold shares that had been reserved for issuance under multiple legacy equity compensation and employee stock purchase plans of Proteostasis Therapeutics, Yumanity Therapeutics and Kineta.

The action follows the completion on 30 June 2025 of the two-step merger in which Kineta became a wholly-owned subsidiary of TuHURA Biosciences, Inc. (First Merger) and was subsequently merged into Hura Merger Sub II, LLC, which now operates as “Kineta, LLC.” Because the merger terminated the underlying employee equity plans, the offerings contemplated by the affected S-8 statements have ended. In accordance with undertakings in each Form S-8, Kineta is formally removing from registration the remaining unissued shares.

Key details:

• 9 Form S-8 registration statements affected (Reg. Nos. 333-210521, 218544, 223664, 230155, 237181, 252691, 252692, 256853, 268969).
• Plans covered include Proteostasis 2008 & 2016 plans, ESPP, Yumanity 2018 & 2021 plans, and Kineta 2008, 2010, 2020 & 2022 plans.
• All remaining shares, including previously assumed awards (e.g., 908,205 option/RSU shares and 2,315,860 reserved shares under the Kineta 2022 EIP), are now deregistered.
• James A. Bianco, M.D., signed the amendment in Tampa, Florida on behalf of Kineta, LLC.

The filing is procedural, has no impact on current share-count reporting at TuHURA, and simply eliminates potential future dilution from the unsold shares.

Kineta, LLC (successor by merger to Kineta, Inc.) has filed nine Post-Effective Amendment No. 1s to previously effective Form S-8 registration statements to deregister all unsold shares that had been reserved for multiple legacy equity incentive and employee stock purchase plans. The administrative action follows the 30 June 2025 closing of the two-step merger in which Kineta became a wholly-owned subsidiary of TuHURA Biosciences, Inc. and was converted into Kineta, LLC. Because the stand-alone plans of Proteostasis Therapeutics, Yumanity Therapeutics and Kineta are now terminated, the related offerings are deemed concluded, triggering removal of the remaining registered securities. The amendments span Registration Statement Nos. 333-210521, 333-218544, 333-223664, 333-230155, 333-237181, 333-252691, 333-252692, 333-256853 and 333-268969, which collectively covered millions of potential shares across the 2008, 2016, 2018, 2020 and 2022 equity plans and various inducement grants. No new securities are being registered, no financial statements are provided, and the filing does not alter the merger consideration already distributed to former Kineta shareholders. The primary effect is the elimination of potential future dilution from the unissued shares and formal alignment of the capital structure with the post-merger entity.

Kineta, LLC (successor by merger to Kineta, Inc.) has filed nine Post-Effective Amendment No. 1s to previously effective Form S-8 registration statements to deregister all unsold shares that had been reserved for multiple legacy equity incentive and employee stock purchase plans. The administrative action follows the 30 June 2025 closing of the two-step merger in which Kineta became a wholly-owned subsidiary of TuHURA Biosciences, Inc. and was converted into Kineta, LLC. Because the stand-alone plans of Proteostasis Therapeutics, Yumanity Therapeutics and Kineta are now terminated, the related offerings are deemed concluded, triggering removal of the remaining registered securities. The amendments span Registration Statement Nos. 333-210521, 333-218544, 333-223664, 333-230155, 333-237181, 333-252691, 333-252692, 333-256853 and 333-268969, which collectively covered millions of potential shares across the 2008, 2016, 2018, 2020 and 2022 equity plans and various inducement grants. No new securities are being registered, no financial statements are provided, and the filing does not alter the merger consideration already distributed to former Kineta shareholders. The primary effect is the elimination of potential future dilution from the unissued shares and formal alignment of the capital structure with the post-merger entity.

Bank of Nova Scotia (BNS) is marketing an SEC-registered Free Writing Prospectus for Market-Linked, auto-callable, contingent coupon notes maturing July 27, 2029. Each $1,000 security is linked to the lowest performer among the Russell 2000, EURO STOXX 50 and Nasdaq-100 indices.

Key economic terms

• Contingent coupon: at least 11.00% p.a., paid quarterly only if the lowest-performing index is ≥ 75% of its starting level on the calculation day.
• Automatic call: beginning January 2026, the note is redeemed at par plus coupon if the lowest index is ≥ its starting level on any quarterly calculation day.
• Principal repayment: at maturity, investors receive $1,000 if the lowest index is ≥ 75% of its starting level; otherwise, repayment equals $1,000 × performance factor, exposing investors to full downside below the 75% threshold.
• Issue price: $1,000; Bank’s estimated value: $915.26–$945.26 (91.526%–94.526%), reflecting dealer spreads (up to 2.575%) and hedging costs.
• Denomination: $1,000; CUSIP 06418VZS6; pricing date July 31 2025; issue date August 5 2025.

Investor considerations

• No fixed interest; coupons and principal depend on quarterly index levels.
• Downside risk: up to 100% capital loss if the worst index falls ≥ 25% by final observation.
• Credit exposure to Bank of Nova Scotia; notes are unsecured and not FDIC-insured.
• Liquidity likely limited; secondary prices may be materially below face value due to fees and market factors.

The term sheet highlights extensive risk factors, including reinvestment risk, index correlation risk, non-U.S. market risk and tax uncertainty. Investors should review the full preliminary pricing supplement and related prospectus documents before investing.

Barclays Bank PLC is marketing Callable Contingent Coupon Notes due August 5, 2030 linked to the worst performer of the S&P 500, Russell 2000 and Nasdaq-100 indices. The securities are unsecured, unsubordinated debt of the bank issued under its Global Medium-Term Note program.

Key structural terms

• Initial issue price: $1,000 per note; minimum investment $1,000.
• Contingent coupon: 0.8333% monthly (10% p.a.) paid only if, on the applicable Observation Date, the closing level of each reference index is at or above 75% of its initial level (“Coupon Barrier”).
• Principal repayment: • 100% if, on the Final Valuation Date (31-Jul-2030), the worst‐performing index is at or above 70% of its initial level (“Barrier”). • Otherwise, investors are fully exposed to the downside of the worst index and may lose up to 100% of principal.
• Issuer call: Barclays may redeem the notes in whole (not in part) on any of 57 scheduled Call Valuation Dates starting 31-Oct-2025. Redemption price equals $1,000 plus any due coupon; no further payments thereafter.
• Estimated value: Barclays’ internal models indicate $888.10–$968.10 per note at pricing—below the $1,000 offer price—reflecting distribution costs, hedging and issuer profit.
• Credit & bail-in risk: Payments depend on Barclays’ solvency and are subject to U.K. bail-in powers, potentially resulting in partial or total loss irrespective of market performance.
• No exchange listing; secondary market, if any, will be made solely by Barclays Capital Inc. and may be illiquid.

Risk highlights

• Investors may receive no coupons if any index closes below its Coupon Barrier on each Observation Date.
• Because performance is judged on the least-performing index, correlation risk is elevated and the likelihood of missed coupons or principal loss is higher than with single-index notes.
• Early redemption is at the issuer’s discretion, creating reinvestment risk that is greatest when the notes are most attractive to holders.
• The notes’ valuation is sensitive to index volatility, correlation, interest rates and Barclays’ credit spreads; secondary prices will likely trail the offer price and could be well below modeled value.

The product suits investors seeking high conditional income who understand equity-index downside risk, limited upside, call exposure and bail-in provisions, and who are comfortable holding unsecured Barclays credit for up to five years.

Barclays Bank PLC is marketing Callable Contingent Coupon Notes due August 5, 2030 linked to the worst performer of the S&P 500, Russell 2000 and Nasdaq-100 indices. The securities are unsecured, unsubordinated debt of the bank issued under its Global Medium-Term Note program.

Key structural terms

• Initial issue price: $1,000 per note; minimum investment $1,000.
• Contingent coupon: 0.8333% monthly (10% p.a.) paid only if, on the applicable Observation Date, the closing level of each reference index is at or above 75% of its initial level (“Coupon Barrier”).
• Principal repayment: • 100% if, on the Final Valuation Date (31-Jul-2030), the worst‐performing index is at or above 70% of its initial level (“Barrier”). • Otherwise, investors are fully exposed to the downside of the worst index and may lose up to 100% of principal.
• Issuer call: Barclays may redeem the notes in whole (not in part) on any of 57 scheduled Call Valuation Dates starting 31-Oct-2025. Redemption price equals $1,000 plus any due coupon; no further payments thereafter.
• Estimated value: Barclays’ internal models indicate $888.10–$968.10 per note at pricing—below the $1,000 offer price—reflecting distribution costs, hedging and issuer profit.
• Credit & bail-in risk: Payments depend on Barclays’ solvency and are subject to U.K. bail-in powers, potentially resulting in partial or total loss irrespective of market performance.
• No exchange listing; secondary market, if any, will be made solely by Barclays Capital Inc. and may be illiquid.

Risk highlights

• Investors may receive no coupons if any index closes below its Coupon Barrier on each Observation Date.
• Because performance is judged on the least-performing index, correlation risk is elevated and the likelihood of missed coupons or principal loss is higher than with single-index notes.
• Early redemption is at the issuer’s discretion, creating reinvestment risk that is greatest when the notes are most attractive to holders.
• The notes’ valuation is sensitive to index volatility, correlation, interest rates and Barclays’ credit spreads; secondary prices will likely trail the offer price and could be well below modeled value.

The product suits investors seeking high conditional income who understand equity-index downside risk, limited upside, call exposure and bail-in provisions, and who are comfortable holding unsecured Barclays credit for up to five years.